Rockwell Medical Q4 Revenue at $18.3M
Reports Q4 revenue $18.3M vs. $24.7M last year. "2025 was a year of transition for Rockwell Medical. We successfully navigated changes in our customer base, purchase volumes, and distribution footprint, all while maintaining profitability on an Adjusted EBITDA basis for the second consecutive year," said CEO Mark Strobeck. "We made significant changes internally to further align our infrastructure with demand. As a result, our gross margin for the full-year 2025 was in line with gross margin for 2024, and we delivered one of the highest quarterly gross margins in the Company's history in Q4 2025. Additionally, in Q4 2025, we generated positive cash flow from operating activities resulting in a higher cash position at year-end. We remain focused on making Rockwell Medical consistently profitable and positioning the Company for long-term stability and success. In 2026, we believe we are well-positioned to build upon this momentum with a clear focus on driving revenue growth, expanding profitability, and further diversifying our portfolio."
Trade with 70% Backtested Accuracy
Analyst Views on RMTI
About RMTI
About the author
Rockwell Medical Q4 2025 Earnings Call Insights Highlight Operational Improvements and Growth Projections
- Customer Base Diversification: Rockwell Medical now serves approximately 300 customers in the U.S., including all five leading dialysis providers, with long-term agreements expected to drive sales growth in 2026, thereby strengthening its market position.
- Financial Performance Improvement: Q4 2025 net sales reached $18.3 million, a 15% increase from Q3, despite a 26% year-over-year decline, while gross margin improved from 14% in Q3 to 21%, indicating sustained profitability enhancements.
- Product Portfolio Expansion: The company introduced a single-use bicarbonate cartridge approved by the FDA 510(k), with expected sales of approximately $1 million in 2026, further enriching its product line and enhancing market competitiveness.
- Optimistic Future Outlook: Management projects adjusted EBITDA for 2026 to be between $1 million and $2 million, with positive cash flow expected to continue, and long-term goals include exceeding $100 million in annual sales by 2029, with gross margins approaching 30%.
Rockwell Medical Reports Q4 Earnings Miss with Strategic Growth Plans for 2026
- Financial Overview: Rockwell Medical reported a Q4 Non-GAAP EPS of $0.02 with revenues of $18.3 million, reflecting a 25.8% year-over-year decline, which missed market expectations and indicates short-term financial challenges for the company.
- Cash Flow Position: Despite the revenue drop, the company generated $2.3 million in cash flow from operating activities in Q4, increasing its cash reserves to $25 million by year-end 2025, providing a buffer for future operations.
- Annual Performance Comparison: In 2025, Rockwell Medical achieved net sales of $69.3 million, aligning closely with its annual guidance of $65 million to $70 million but falling short of the market consensus of $75.15 million, highlighting intensified market competition.
- Future Growth Strategy: The company aims to drive sustainable, profitable growth in 2026 by adding new customers, renewing existing contracts, improving pricing and product mix, enhancing operational efficiencies, and selectively expanding its portfolio through disciplined partnerships, projecting Adjusted EBITDA between $1 million and $2 million.
Rockwell Medical Reports Q4 Adjusted EPS of $0.02
Company Overview: Rockwell Medical is a healthcare company focused on developing and commercializing innovative products for the treatment of kidney disease and related conditions.
Financial Performance: The company reported adjusted earnings per share (EPS) of $0.02 for the fourth quarter, indicating a positive financial outlook.
Product Development: Rockwell Medical continues to advance its product pipeline, aiming to enhance treatment options for patients with chronic kidney disease.
Market Position: The company is positioning itself strategically within the medical industry to address unmet needs in kidney care, potentially expanding its market share.
Rockwell Medical Reports Q4 Net Loss of $600,000
Company Overview: Rockwell Medical is a healthcare company focused on developing and commercializing innovative products for the treatment of end-stage renal disease and chronic kidney disease.
Financial Performance: The company reported a net income of $600,000 for the fourth quarter, indicating a positive financial trend and potential growth in their market segment.
Rockwell Medical Set to Announce Q4 Earnings on March 26
- Earnings Announcement Schedule: Rockwell Medical (RMTI) is set to announce its Q4 2023 earnings on March 26 before the market opens, with a consensus EPS estimate of $0.02, reflecting a 50% year-over-year decline.
- Revenue Expectations Decline: Analysts forecast RMTI's Q4 revenue at $18.58 million, representing a 24.7% year-over-year decrease, indicating challenges and pressures the company faces in the current market environment.
- Historical Performance Review: Over the past two years, RMTI has beaten EPS estimates 50% of the time and revenue estimates 63% of the time, demonstrating a degree of volatility in the company's financial performance.
- Increased Market Attention: As the earnings report approaches, investor interest in Rockwell Medical is rising, particularly in light of preliminary sales data exceeding expectations, which may influence market perceptions of its future performance.
Rockwell Medical (RMTI) Reports 2025 Revenue Decline but Gross Margin Improvement
- Revenue Decline Expected: Rockwell Medical anticipates fourth-quarter net sales of approximately $18.6 million for 2025, down from $24.7 million in the prior year, indicating pressure in market competition.
- Full-Year Performance Drop: The expected full-year net sales for 2025 are around $69.5 million, lower than the $101.5 million reported last year, reflecting challenges in revenue growth for the company.
- Gross Margin Improvement: Despite the revenue decline, Rockwell Medical's gross margin for the fourth quarter increased to approximately 22% from 15% in the previous year, indicating progress in cost control and profitability.
- Future Strategic Focus: CEO Mark Strobeck stated that Rockwell will concentrate on revenue growth, increased profitability, and portfolio diversification in 2026, aiming to address current market challenges through these strategic initiatives.
Rockwell Medical Q4 2025 Earnings Call Insights Highlight Operational Improvements and Growth Projections
- Customer Base Diversification: Rockwell Medical now serves approximately 300 customers in the U.S., including all five leading dialysis providers, with long-term agreements expected to drive sales growth in 2026, thereby strengthening its market position.
- Financial Performance Improvement: Q4 2025 net sales reached $18.3 million, a 15% increase from Q3, despite a 26% year-over-year decline, while gross margin improved from 14% in Q3 to 21%, indicating sustained profitability enhancements.
- Product Portfolio Expansion: The company introduced a single-use bicarbonate cartridge approved by the FDA 510(k), with expected sales of approximately $1 million in 2026, further enriching its product line and enhancing market competitiveness.
- Optimistic Future Outlook: Management projects adjusted EBITDA for 2026 to be between $1 million and $2 million, with positive cash flow expected to continue, and long-term goals include exceeding $100 million in annual sales by 2029, with gross margins approaching 30%.
Rockwell Medical Reports Q4 Earnings Miss with Strategic Growth Plans for 2026
- Financial Overview: Rockwell Medical reported a Q4 Non-GAAP EPS of $0.02 with revenues of $18.3 million, reflecting a 25.8% year-over-year decline, which missed market expectations and indicates short-term financial challenges for the company.
- Cash Flow Position: Despite the revenue drop, the company generated $2.3 million in cash flow from operating activities in Q4, increasing its cash reserves to $25 million by year-end 2025, providing a buffer for future operations.
- Annual Performance Comparison: In 2025, Rockwell Medical achieved net sales of $69.3 million, aligning closely with its annual guidance of $65 million to $70 million but falling short of the market consensus of $75.15 million, highlighting intensified market competition.
- Future Growth Strategy: The company aims to drive sustainable, profitable growth in 2026 by adding new customers, renewing existing contracts, improving pricing and product mix, enhancing operational efficiencies, and selectively expanding its portfolio through disciplined partnerships, projecting Adjusted EBITDA between $1 million and $2 million.
Rockwell Medical Reports Q4 Adjusted EPS of $0.02
Company Overview: Rockwell Medical is a healthcare company focused on developing and commercializing innovative products for the treatment of kidney disease and related conditions.
Financial Performance: The company reported adjusted earnings per share (EPS) of $0.02 for the fourth quarter, indicating a positive financial outlook.
Product Development: Rockwell Medical continues to advance its product pipeline, aiming to enhance treatment options for patients with chronic kidney disease.
Market Position: The company is positioning itself strategically within the medical industry to address unmet needs in kidney care, potentially expanding its market share.
Rockwell Medical Reports Q4 Net Loss of $600,000
Company Overview: Rockwell Medical is a healthcare company focused on developing and commercializing innovative products for the treatment of end-stage renal disease and chronic kidney disease.
Financial Performance: The company reported a net income of $600,000 for the fourth quarter, indicating a positive financial trend and potential growth in their market segment.
Rockwell Medical Set to Announce Q4 Earnings on March 26
- Earnings Announcement Schedule: Rockwell Medical (RMTI) is set to announce its Q4 2023 earnings on March 26 before the market opens, with a consensus EPS estimate of $0.02, reflecting a 50% year-over-year decline.
- Revenue Expectations Decline: Analysts forecast RMTI's Q4 revenue at $18.58 million, representing a 24.7% year-over-year decrease, indicating challenges and pressures the company faces in the current market environment.
- Historical Performance Review: Over the past two years, RMTI has beaten EPS estimates 50% of the time and revenue estimates 63% of the time, demonstrating a degree of volatility in the company's financial performance.
- Increased Market Attention: As the earnings report approaches, investor interest in Rockwell Medical is rising, particularly in light of preliminary sales data exceeding expectations, which may influence market perceptions of its future performance.
Rockwell Medical (RMTI) Reports 2025 Revenue Decline but Gross Margin Improvement
- Revenue Decline Expected: Rockwell Medical anticipates fourth-quarter net sales of approximately $18.6 million for 2025, down from $24.7 million in the prior year, indicating pressure in market competition.
- Full-Year Performance Drop: The expected full-year net sales for 2025 are around $69.5 million, lower than the $101.5 million reported last year, reflecting challenges in revenue growth for the company.
- Gross Margin Improvement: Despite the revenue decline, Rockwell Medical's gross margin for the fourth quarter increased to approximately 22% from 15% in the previous year, indicating progress in cost control and profitability.
- Future Strategic Focus: CEO Mark Strobeck stated that Rockwell will concentrate on revenue growth, increased profitability, and portfolio diversification in 2026, aiming to address current market challenges through these strategic initiatives.
